Baltimore Beauty offered GenBody COVID-19 test kits directly to consumers without FDA approval, clearance, or authorization.
What happened
FDA found this by reviewing the business's offerings, not through an inspection, and says the business offers the GenBody COVID-19 Ag test and GenBody COVID-19 IgM/IgG test directly to consumers in the United States. FDA says the tests were offered without marketing approval, clearance, or authorization. The letter also states that the GenBody COVID-19 IgM/IgG test is on FDA's “removed” serology test list and should not be distributed unless authorized.
What FDA found
The company offered COVID-19 test kits for sale directly to consumers without FDA marketing approval, clearance, or authorization.
section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B)The company did not notify FDA of its intent to introduce the devices into commercial distribution as required by section 510(k).
section 502(o) of the Act, 21 U.S.C. § 352(o); section 510(k), 21 U.S.C. § 360(k)The company introduced or delivered the products into interstate commerce, which is prohibited.
section 301(a), 21 U.S.C. § 331(a)The company did acts with respect to the devices while they were held for sale after interstate shipment, resulting in the devices being misbranded.
section 301(k), 21 U.S.C. § 331(k)
What FDA wants
FDA asks the company to stop selling the unapproved, uncleared, and unauthorized COVID-19 test kits immediately and to email COVID-19-Task-Force-CDRH@fda.hhs.gov within 48 hours with the steps taken, documentation, and plans to prevent recurrence. If it cannot complete the action in 48 hours, it must state why and give a timeframe.
Who should pay attention
- consumers buying COVID-19 tests online or in retail stores
- retailers and online marketplaces offering third-party test kits
- distributors or brands handling GenBody COVID-19 tests
This is a summary. Read the original letter on fda.gov.